Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and delivering novel therapies for central nervous system (CNS) disorders where treatment options are limited. The company's mission is to transform the approach to treating CNS conditions by accelerating the invention and adoption of life-changing medicines that meaningfully improve the lives of patients. Headquartered in New York, NY, at One World Trade Center, Axsome focuses on addressing unmet medical needs in neurology and psychiatry.

Axsome's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), approved for major depressive disorder (MDD) and recently for agitation associated with Alzheimer's disease (ADA). Another key product is Sunosi (solriamfetol), used to treat excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The company also has SYMBRAVO, approved for the acute treatment of migraine. Its robust pipeline features candidates like AXS-12 for narcolepsy and AXS-14 for fibromyalgia, alongside further development of solriamfetol for conditions such as ADHD and major depressive disorder with excessive daytime sleepiness.

In a significant development, Axsome Therapeutics received FDA approval for Auvelity (AXS-05) for agitation associated with Alzheimer's disease on April 30, 2026, marking a substantial market opportunity. The commercial launch for this indication is anticipated in June 2026. Led by CEO and Chairman Dr. Herriot Tabuteau, the company has demonstrated strong revenue growth from its existing products, Auvelity and Sunosi, and is strategically positioned for further expansion within the neuroscience sector with a late-stage pipeline targeting numerous unmet medical needs.

Latest updates

Axsome Highlights AUVELITY Approval, Eyes Dementia Agitation Market

Event summary

  • Axsome Therapeutics held an investor event on May 1, 2026, to discuss FDA approval of AUVELITY for agitation associated with dementia due to Alzheimer’s disease.
  • Dr. Jeffrey Cummings, a recognized Alzheimer’s researcher, presented on the condition and AUVELITY’s potential role in treatment.
  • AUVELITY is a first-in-class treatment targeting NMDA and sigma-1 receptors, approved initially in 2022 for major depressive disorder.
  • The drug is protected by patents extending to at least 2043.

The big picture

The approval of AUVELITY represents a significant opportunity for Axsome in a largely underserved market, as agitation in dementia patients is a common and debilitating condition often leading to institutionalization. The company’s focus on novel mechanisms of action within CNS disorders positions it to capitalize on unmet medical needs, but success hinges on navigating payer access and demonstrating long-term clinical benefit. The timing of this approval, following earlier approvals for MDD, suggests a broader strategy to leverage AUVELITY’s platform across multiple CNS indications.

What we're watching

Market Adoption
The speed of AUVELITY’s adoption within the Alzheimer’s dementia care pathway will depend on physician familiarity and payer reimbursement decisions, given the complexity of agitation management.
Competitive Landscape
While AUVELITY is first-in-class, the emergence of alternative therapies or novel treatment approaches for agitation in dementia could erode its market share over time.
Commercial Execution
Axsome’s ability to effectively communicate AUVELITY’s value proposition to physicians and caregivers, and to build a robust commercial infrastructure, will be critical for driving revenue growth.

Axsome Gains FDA Approval for Alzheimer's Agitation Treatment, AUVELITY

Event summary

  • Axsome Therapeutics received FDA approval for AUVELITY (dextromethorphan HBr and bupropion HCl) to treat agitation associated with dementia due to Alzheimer’s disease.
  • AUVELITY is a first-in-class treatment targeting NMDA and sigma-1 receptors, developed under FDA Breakthrough Therapy and Priority Review designations.
  • Clinical trials (ADVANCE-1 and ACCORD-2) demonstrated AUVELITY's superiority over placebo in agitation symptom improvement and longer relapse times.
  • The approval marks Axsome's second FDA Breakthrough Therapy designation for AUVELITY, following its approval for major depressive disorder.

The big picture

The approval addresses a significant unmet need in Alzheimer’s care, as agitation affects a large percentage of patients and contributes to caregiver burden and increased healthcare costs. Axsome’s success hinges on demonstrating a clear clinical and economic advantage over existing off-label treatments and navigating the complexities of the Alzheimer’s market, which is characterized by high development costs and regulatory hurdles. The company's broader pipeline and reliance on AUVELITY's success will be closely monitored.

What we're watching

Commercialization
The success of AUVELITY will depend on Axsome’s ability to effectively reach clinicians and patients, particularly given the complexity of Alzheimer’s diagnosis and treatment, and the availability of the OnMySide patient support program.
Payer Adoption
Reimbursement coverage from insurance providers will be critical for AUVELITY’s uptake; the company's pricing strategy and ability to demonstrate cost-effectiveness will be key factors.
Competitive Landscape
While AUVELITY is first-in-class, the Alzheimer’s space is attracting increased attention, and the emergence of alternative therapies or approaches could erode AUVELITY’s market share over time.
CID: 1461